Skip to content
1887

Abstract

Human papillomavirus (HPV), the predominant viral infection affecting the anogenital tract, is closely linked to the development of intraepithelial neoplasia and malignancies in the cervix and other anal regions. Currently, 15 high-risk HPVs (HR-HPVs) and 3 potential HR-HPV types have been recognized as contributors to cervical cancer. Consequently, it is imperative to conduct HR-HPV screening using suitable tests in order to identify precancerous lesions and prevent the development of cancer.

The Human papillomavirus genotyping (type 23) detection kit (PCR-reverse point hybridization method) is reliable for clinical testing.

The objective of this research was to assess the concordance between the Human papillomavirus genotyping (type 23) detection kit (PCR-reverse point hybridization method) and the approved HPV test.

A sample of 781 women who received HPV genotype testing during cervical cancer screening consultations at the Department of Gynecology, Fujian Maternity and Child Health Hospital, was examined. Thirty-two cases were excluded for lacking histological results or showing signs of vulvar intraepithelial rheology, leaving 749 valid histological samples. Only 181 valid pathological specimens were available after excluding those without cervical biopsy or total hysterectomy. The consistency of the test results was assessed using the kappa () statistic, with CIN2+ serving as the benchmark for determining sensitivity and specificity. Statistical significance was defined as differences with values <0.05 (two-tailed).

The human papillomavirus genotyping (type 23) detection kit (PCR-reverse point hybridization method) and the approved HPV test demonstrated a high level of concordance with a total kappa value of 0.969 (<0.05). The overall concordance rate was found to be 98.720%. Using cervical intraepithelial neoplasia grade 2+ (CIN2+) as the reference standard, the human papillomavirus genotyping (type 23) detection kit (PCR-reverse point hybridization method) and the approved HPV test both showed 89.655% sensitivity (>0.05), while the specificity values were 40.590 and 40.309%, respectively (>0.05).

The evaluated HPV test demonstrates comparable performance to other assays available during the same time frame and exhibits strong concordance in detecting the majority of HPV genotypes.

Funding
This study was supported by the:
  • Fujian Provincial Health Technology Project (Award 2020Y9402)
    • Principal Award Recipient: LiangzhiCai
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001938
2024-12-13
2025-11-15

Metrics

Loading full text...

Full text loading...

References

  1. Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health 2023; 11:e197–e206 [View Article] [PubMed]
    [Google Scholar]
  2. Dube Mandishora RS, Gjøtterud KS, Lagström S, Stray-Pedersen B, Duri K et al. Intra-host sequence variability in human papillomavirus. Papillomavirus Res 2018; 5:180–191 [View Article] [PubMed]
    [Google Scholar]
  3. Elst L, Albersen M. HPV vaccination: does it have a role in preventing penile cancer and other preneoplastic lesions?. Semin Oncol Nurs 2022; 38:151284 [View Article] [PubMed]
    [Google Scholar]
  4. Lechner M, Liu J, Masterson L, Fenton TR. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol 2022; 19:306–327 [View Article] [PubMed]
    [Google Scholar]
  5. Rakislova N, Saco A, Sierra A, Del Pino M, Ordi J. Role of human papillomavirus in vulvar cancer. Adv Anat Pathol 2017; 24:201–214 [View Article] [PubMed]
    [Google Scholar]
  6. Halec G, Alemany L, Lloveras B, Schmitt M, Alejo M et al. Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol 2014; 234:441–451 [View Article] [PubMed]
    [Google Scholar]
  7. Sadri Nahand J, Moghoofei M, Salmaninejad A, Bahmanpour Z, Karimzadeh M et al. Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: a review. Int J Cancer 2020; 146:305–320 [View Article] [PubMed]
    [Google Scholar]
  8. Assefa AA, Astawesegn FH, Eshetu B. Cervical cancer screening service utilization and associated factors among HIV positive women attending adult ART clinic in public health facilities, Hawassa town, Ethiopia: a cross-sectional study. BMC Health Serv Res 2019; 19:847 [View Article] [PubMed]
    [Google Scholar]
  9. Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009; 10:672–682 [View Article] [PubMed]
    [Google Scholar]
  10. Verma I, Jain V, Kaur T. Application of bethesda system for cervical cytology in unhealthy cervix. J Clin Diagn Res 2014; 8:C26–C30 [View Article] [PubMed]
    [Google Scholar]
  11. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11:1048–1056 [View Article] [PubMed]
    [Google Scholar]
  12. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjosé S et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012; 131:2349–2359 [View Article] [PubMed]
    [Google Scholar]
  13. Chen W, Zhang X, Molijn A, Jenkins D, Shi J-F et al. Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18. Cancer Causes Control 2009; 20:1705–1713 [View Article] [PubMed]
    [Google Scholar]
  14. Szarewski A, Mesher D, Cadman L, Austin J, Ashdown-Barr L et al. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J Clin Microbiol 2012; 50:1867–1873 [View Article] [PubMed]
    [Google Scholar]
  15. Nakamura M, Nakade K, Orisaka S, Iwadare J, Mizumoto Y et al. Comparison study of BD onclarity HPV with digene HC2 high-risk HPV DNA test and Roche Cobas 4800 HPV for detecting high-risk human papillomavirus in Japan. Am J Clin Pathol 2019; 151:263–269 [View Article] [PubMed]
    [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.001938
Loading
/content/journal/jmm/10.1099/jmm.0.001938
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An error occurred
Approval was partially successful, following selected items could not be processed due to error